Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems

Author:

Li Ang1ORCID,La Jennifer2ORCID,May Sarah B.3ORCID,Guffey Danielle3,da Costa Wilson L.4ORCID,Amos Christopher I.34ORCID,Bandyo Raka5,Milner Emily M.6,Kurian Karen M.6ORCID,Chen Daniel C.R.27ORCID,Do Nhan V.27ORCID,Granada Carolina1ORCID,Riaz Nimrah1ORCID,Brophy Mary T.28,Chitalia Vipul2910ORCID,Gaziano J. Michael21112,Garcia David A.13,Carrier Marc14ORCID,Flowers Christopher R.15ORCID,Zakai Neil A.16ORCID,Fillmore Nathanael R.281117ORCID

Affiliation:

1. Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX

2. Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA

3. Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX

4. Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX

5. Harris Health System, Houston, TX

6. School of Medicine, Baylor College of Medicine, Houston, TX

7. Section of General Internal Medicine, Boston University School of Medicine, Boston, MA

8. Section of Hematology & Medical Oncology, Boston University School of Medicine, Boston, MA

9. Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA

10. Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA

11. Department of Medicine, Harvard Medical School, Boston, MA

12. Division of Aging, Brigham and Women's Hospital, Boston, MA

13. Division of Hematology, University of Washington School of Medicine, Seattle, WA

14. Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

15. Division of Cancer Medicine, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

16. Departments of Medicine and Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT

17. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Abstract

PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy. METHODS Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage and selection operator regression from the Harris Health System (HHS, n = 9,769) and externally validated it using the Veterans Affairs (VA) health care system (n = 79,517). Bootstrapped c statistics and calibration curves were used to assess external model discrimination and fit. Dichotomized risk strata using integer scores were created and compared against the Khorana score (KS). RESULTS Incident VTE and PE/LE-DVT at 6 months occurred in 590 (6.2%) and 437 (4.6%) patients in HHS and 4,027 (5.1%) and 3,331 (4.2%) patients in the VA health care system. Assessed at the time of systemic therapy initiation, the new RAM included components of the KS with the modified cancer subtype, cancer staging, systemic therapy class, history of VTE, history of paralysis/immobility, recent hospitalization, and Asian/Pacific Islander race. The c statistic was 0.71 in HHS and 0.68 in the VA health care system (compared with 0.65 and 0.60, respectively, for KS). Furthermore, the new RAM appropriately reclassified 28% of patients and increased the proportion of VTEs in the high-risk group from 37% to 68% in the validation data set. CONCLUSION The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months ( v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies. [Media: see text]

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3